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Abstract 
Coacervation technique was implemented in fabrication of BSA nanoparticle for the purpose of 
drug delivery system. Nanoparticle was purified with 48,800 g centrifuge, and then followed by 
dialysis, micro and ultra filtration. The fabricated nanoparticles were subjected to physical, 
morphological and biochemical characterization. The analyzed samples by SEM and AFM 
proved the semi-spherically shape of the particles whilst the size distribution was measured by 
photon correlation spectroscopy. Fourier transforms infra-red spectroscopy (FTIR) spectrum 
indicated that the fabricated nanoparticles were pure. The impact of various parameters upon the 
particle size was extensively investigated. The concentration of glutaraldehyde at fixed 
temperature had absolutely no significant effect on the size of particles. The affecting parameter 
was modeled to predict the size of nanoparticle. At low temperature (4°C), the nanoparticle size 
of 89.3nm was fabricated with pure BSA concentration of 20 mg.ml-1. 
 
 
 
Keywords: Bovine serum albumin, nanoparticles, pure protein, coacervation, nanosphere, semi-
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Introduction 
Over the past few decades, there has been considerable interest in developing biodegradable 
nanoparticle (liposome, virus like particle (VLP), protein and etc.) as effective drug delivery 
devices1,2,3,4.  Nanoparticles of biodegradable polymers are sustainable and well controlled for 
targeted drug delivery. This method may improve the therapeutic effects and reduce the side 
effects of the formulated drugs5, 6.  An important advantage associated with the use of 
nanoparticles includes the ease of preparation from well-understood biodegradable polymers and 
high stability in biological fluids and long duration for storage7,8. Nanoparticles size is defined as 
particle size of well below 1000 nm. When the drug is encapsulated by the nanoparticle, the 
product is known as nanocapsulated particle. If the medicine is uniformly coated on the exterior 
of the nanoparticle then, it is called nanosphere. Schematic diagram of nanocapsulated and 
nanosphere particles loaded with drug are shown in Figure 1. 
 
The carrier itself should be non-toxic and biodegradable so that it does not accumulate 
indefinitely in tissues 9. Also, the biodegradable nano- and microparticles are stated to be very 
useful delivery devices for various active agents10. Albumin nanoparticles have extensively been 
investigated as appropriate drug delivery system because of their biodegradable property, non-
toxic and non antigenic11,12. The particles are defined in primary structure and contained high 
amount of charged amino acids (i.e. lysine). The albumin-based nanoparticles could allow the 
electrostatic adsorption of positively or negatively charged molecules without the requirements 
of any other compounds. In addition, protein nanoparticles can easily be prepared by 
coacervation or controlled desolvation processes13,14. Several methods have been developed for 
the preparation of albumin nanoparticles, such as emulsification, coacervation or desolvation. 
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Emulsification method is used by means of an aqueous albumin solution is emulsified in an oily 
phase and subsequently precipitated by heat treatment. This technique usually leads to formation 
of microparticles16,17. Recently, nanoparticles fabrications by coacervation methods are 
reported11,16. A desolving agent (e.g. a salt solution, alcohol, and acetone) was added to an 
aqueous Bovine Serum Albumin (BSA) solution in order to dehydrate the gelatin molecules. 
That is resulted in change in conformation of stretched to coiled, which is indicated by turbidity 
in the aqueous phase. Then, a cross-linking agent is added to harden the native particles18,19,20. 
The preparation conditions for colloidal drug carrier nanoparticles should be controlled in order 
to have particle size of less than 200nm13. 
 
The purpose of present research paper was to fabricate nanoparticles in a unique range which is 
suitable for the drug delivery system. The effect of manufacturing conditions such as pH, BSA 
concentration, agitation speed, rate of additional organic solvent was extensively investigated. 
The characteristics of the fabricated protein nanoparticles were modeled and the affect of the 
influential parameters on particle size were discussed. 
 
2. Materials and Methods 
2.1. Materials 
Bovine serum albumin (BSA) (fraction V, with purity of 98%), Tween-20, ethanolamine and 
glutaraldehyde, 25% solution, were commercially supplied by Sigma Aldrich. Analytical grade 
and high purity of sodium azide and all other chemicals were supplied from Merck (Germany).  
 
2.2. Preparation of BSA Nanoparticles 
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Coacervation technique was implemented for preparation of BSA nanoparticles [19]. Anhydrous 
ethyl alcohol was added to 150 ml BSA (5 mg/l in 10 mM Tris/HCl contained 0.02% sodium 
azide, pH 7.5) till the solution became turbid, then 150 μl of 25% glutaraldehyde was added for 
cross linking. The reaction was continued at room temperature (24°C). Ethanolamine was added 
to block the non-reacted aldehyde functional group. Also Tween-20 was added at a final 
concentration of 0.01% v/v to stabilize the preparation. Large aggregates were eliminated by 
centrifuge (50, 000 g, 30 min, 4°C). The supernatant was dialyzed and subsequently micro and 
ultra filtrated through an acetate membrane and polyvinylchloride copolymer membrane with cut 
off of 0.2 μm and 300 kDa, respectively. The concentration of BSA determined with Coomassie 
Blue reagent21. The size distribution and shape of BSA nanoparticles were determined by 
scanning electronic microscope (SEM)22.  
 
2.3. Determination of Nanoparticle Size and Distribution 
The size distribution of the prepared BSA nanoparticle was analyzed by photon correlation 
spectroscopy (PCS). PCS is industrially preferred method for sub-micron particle size analysis. 
The sample analyzed in PCS device should consist of well dispersed particles in liquid medium. 
In the specified condition, the particles possess in constant random motion, which is refer to 
Brownian motion using Einstein-diffusion equation stated below: 
 
[1] 
 
PCS measures the speed of this motion by passing laser beam. Equation (1) is used in PCS for 
projection of the particle size. As a result of Brownian motion, particles migrate an average 
ArN62 πη
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distance (δ) in a short time interval (T). The diameter of the particles can be determined from the 
Einstein-diffusion equation where D is the diffusion coefficient, NA is Avogadro’s number, and 
R is the gas constant and T absolute temperature.  PCS determined the average particle size and 
Polydispersity Index (PI) which is the measurement for the range of particle sizes within the 
measured sample particles. This index is dimensionless, that is the average molecular weight of 
all nanoparticles to a number of particles that is in the range of 0.05 to 0.7. Generally, this index 
is always less than 0.7. 
 
2.4. Morphology 
The morphologies of the BSA nanoparticles were observed by Atomic Force Microscope (AFM) 
and Scanning Electron Microscope (SEM). The sample was examined under AFM using Philips 
model class 11 Laser productions; Netherland, at 600-700nm wave length. Surface profiles were 
generated from AFM, raw data by the SISCANPRO software (vs. 1.3, Surface Imaging 
Systems). 
 
To take the image with scanning electron microscopy (SEM), fifty microlitres of the nanoparticle 
preparation were freeze dried (EMITECH; Model IK750, Cambridge, UK) on a polished 
aluminum surface. After drying, the sample was sputtered with gold for 30s under Polaron 
machine (BAL-TEC, Model SCDOOS, Switzerland). Afterwards, SEM was performed with a 
Stereoscan S360 Brand SEM-Leica (Cambridge, UK) with the upper detector at 15 kV. The 
magnification was set at 65,000.  
 
2.5. Determination of Particle Purity  
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The purity of BSA nanoparticles was investigated by Fourier Transform Infra-Red (FTIR) 
Spectroscopy (Perkin Elemer Instruments, UK). The samples for FTIR analysis were prepared by 
grinding 99% KBr with 1% nanoparticles and then pressing the mixture into a transparent tablet. 
Phasmatophotometer was employed and Fourier nanoparticle samples were scanned at IR range 
of 450-5000 cm-1. Detector has to be purged by clean dry helium gas (He) to amplify the signal 
level and reduce the moisture.  
 
3. Results and Discussion: 
3.1. Particle size and distribution 
Wide range of protein (BSA) nanoparticles having unique particles size and anionic characters to 
other nanoparticles such as adenovirus and plasmid DNA were fabricated. Based on size 
distribution, average particle size was measured by PCS. The average diameter and 
polydispersity of all samples in several batches were analyzed at room temperature with a 
scattering angle of 900. The size of nanoparticle which is dominant and has the maximum 
percentage in the suspension introduced as a mean size.  Figure 2 exhibits the suspension of BSA 
nanoparticle size analyzed by PCS. The mean size was 226.2 nm and polydispersity Index was 
0.117. The low value of PI showed that the samples had very well dispersity of the particles (less 
than 0.7). The values obtained for all of the fabricated nanoparticles were below 0.7; that means 
all of the prepared samples were quite well dispersed and uniformed.  
 
3.2. Physical Characterization of Nanoparticles 
For determination of the nanoparticles properties (morphology and purity), the samples were 
randomly taken and the reported data were in triplicates. AFM technique has been widely 
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applied to provide surface and morphological information in nanoscale. Figure 3 depicts the 
images of the shape and the surface characteristic of the nanoparticles were successfully obtained 
by Atomic Force Microscopy (AFM).  It was shown that the fabricated nanoparticles were almost 
having a smooth surface. Along with these characteristics, BSA nanoparticles proposed to be a 
suitable candidate for loading drugs on/in the nanoparticles. Two and three dimensional images 
of BSA nanoparticle are shown in Figure 3a and b. The outer surface of the sample particle was 
analyzed by AFM. The sample was prepared in the solution at pH of 7.5, temperature 24°C, 
concentration of 15mg.ml-1 and 200rpm.  
 
Figure 4 shows the SEM image of the outer surface of the nanoparticles. The SEM images show 
the morphology of particle surface and size distribution of the fabricated nanoparticles. It was 
clear that most of the morphologies of the fabricated protein nanoparticles were semispheres 
with diameter in the range of 60 to 300 nm. Monograms were obtained from AFM and SEM 
image.  The resulted nanoparticles were uniformly distributed. The smooth surfaces of the 
fabricated particles are shown with magnification of 14588. 
 
3.3 Purity of the BSA nanoparticles  
Figure 5 shows the Fourier transform infra-red (FTIR) spectroscopy of pure BSA, nanoparticles 
comprised of BSA without purification and purified BSA nanoparticles. FTIR analysis was used 
for determining the purity of the fabricated nanoparticle.  The sample was prepared and analyzed 
at the general condition (pH value of 7, temperature 24ºC, BSA concentration 5mg.ml-1and 200 
rpm agitation). The base for comparison is the standard BSA with the pure and impure BSA 
samples. It is clear from the FTIR spectrum that at the specific range of 4000 to nearly 1500 cm-1 
wavelength, the purification of BSA nanoparticles was well accomplished. Also, the molecular 
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structure of the resulted BSA nanoparticle was characterized by gel electrophoresis SDS-PAGE 
and results were published elsewhere23. 
 
3.4. Analysis of the Fabricated Nanoparticles 
Figure 6 presents the linear model fitted with the experimental data for the size of fabricated 
particles with respected to agitation rate in the range of 200 to 700 rpm, at 4, 14 and 24oC. The 
model is fairly fitted with the experimental data and the slope of the lines increased as the 
temperature increased. However at high agitation rate, the size of particle was decreased. At low 
temperature, the agitation rate was insignificant with respect to fabricated nanoparticle size, but 
the size of the particle was increased as the temperature increased. 
 
The effects of addition of desolvation agent on the size of nanoparticles were investigated with 
respect ethanol flow rate of 0.5, 1, 1.5 and 2 ml.min-1 and temperature range of 4 to 24ºC at fixed 
BSA concentration. Figure 7 depicts, the rate of ethanol addition had no significant effect on size 
of the prepared nanoparticles. However as the temperature increased, the size of nanoparticles 
were increased which was independent of ethanol flow rate. 
 
The effect of pH on size of nanoparticles is shown in Figure 8. The size of nanoparticle was 
maximized at pH value of 6. The size of nanoparticle at acidic and alkaline conditions was 
reduced. Generally, proteins are sensitive to pH, their activities are dependent on pH. The effect 
of pH on size of nanoparticles with respect to temperature (4, 14 and 24 ºC) was examined. The 
highest nanoparticle diameter was observed at pH value around the isoelectric point. At the 
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isoelectric pH value the fabricated nanoparticles became unstable and average particle diameter 
increased up to 163, 204 and 214 nanometer at 4, 14 and 24 ºC, respectively.  
    
In preparation of nanoparticle cross linking are particularly useful for delivering the 
macrosolutes and may serve as drug therapeutic agents8. Effects of glutaraldehyde concentrations 
in nanoparticle fabrication as cross linking agents were investigated.  The particles were 
fabricated with various amounts of the cross linking agent. The fabricated nanoparticles were 
cross linked by glutaraldehyde after the desolvation agent (coacervation method).  
 
Figure 9 presents the effect of glutaraldehyde concentration on size of the fabricated 
nanoparticles at 4, 14 and 24oC. It is obvious to observe that increasing temperature had no 
significant effect on nanoparticle size, but the amount of cross linking agent was not observed to 
be influential in the resulted particles diameter from PCS. The dash lines show the fitted data as 
linear model. 
 
In contrast to the poor influence of the glutaraldehyde concentration and the rate of ethanol 
addition, the BSA concentration in the solution before addition of desolvation agent, which was 
strongly influenced on diameter of the nanoparticle (Figure 10) The effect of BSA concentration 
(5, 10, 15, 20 and 30 mg.l-1) on size of particles diameter at three different temperatures was 
discussed. As the temperature increased, the size of nanoparticles was increased. However at 
high concentration of BSA, the size was gradually decreased. The obtained experimental data 
were perfectly fitted with the projected linear model. This research indicated that the fabricated 
BSA nanoparticle by coacervation technique with average size has good ability for drug delivery 
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system because of  the nanoparticles diameter below 100nm are often used for drug delivery 
systems24.  The fabricated BSA nanoparticles were below 100nm. This option is very important 
for drug delivery systems. It has been reported that the nanoparticles have very good intracellular 
uptake when the nanoparticle diameter was decreased25,26.   
 
Conclusion 
BSA nanoparticles were fabricated with predictable and reproducible size of less than 200 nm; 
by coacervation procedure. The size of nanoparticle obtained at 4°C drastically lower than the 
other temperature (minimum size of particle was 89.3 nm at 20 mg.ml-1 concentration of BSA). 
AFM and SEM analysis from different samples indicated that the fabricated nanoparticles were 
nanosphere and semi spherical shape. Optimization studies for the fabrication of nanoparticulate 
in aspect of recovery of nanoparticle from the initial solution was excluded and subjected to 
future research. 
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a: Entrapped drug b: Surface adsorbed drug
Figure 1| Schematic diagram of the encapsulated and coated nanoparticle for the drug 
delivery system. 
 
 
 
Figure 2| Photon correlation spectroscopy of the BSA 
nanoparticles 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.2
96
6.
1 
: P
os
te
d 
22
 M
ar
 2
00
9
 15
 
 
 
  
b: Two dimensional image of the outer 
surface for dilute solution 
a: Three dimensional image of the outer surface 
for dilute solution 
Figure 3| Atomic force microscopy of the outer surface of the BSA nanoparticles 
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Figure 4| Scanning electronic microscopy of the outer surface of 
the BSA Nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
Figure 5| FTIR analysis of BSA nanoparticle 
 
 
Cm-1 
 4000                 3000                     2000                      1500                    1000          
Pure BSA 
BSA nanoparticle without purification 
BSA nanoparticle after purification 
Tr
an
sm
itt
an
ce
 (%
) 
5 
   
   
 1
5 
   
   
 2
5 
   
   
 3
5 
   
   
 4
5 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.2
96
6.
1 
: P
os
te
d 
22
 M
ar
 2
00
9
 17
Agitation Speed (rpm)
Si
ze
(n
m
)
200 300 400 500 600 700
105
140
175
210
24o C
14o C
4o C
 
Figure 6| The effect of agitation speed on the particle size 
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Figure 7| The effect of rate of addition of Ethanol (ml.min-1) on 
the particle size 
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Figure 8| The effect of pH on the average size of particles. 
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Figure 9| The effect of glutaraldehyde concentration on the 
particle size 
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Figure 10| The effect of BSA concentration on the particle size 
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